Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C43H53N5O8S |
Molecular Weight | 799.975 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2C(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](CC(=O)N4CCCCC4)C(C)(C)C)C(=O)N[C@@]5(C[C@H]5C=C)C(=O)NS(=O)(=O)C6CC6)=CC(=NC2=C1)C7=CC=CC=C7
InChI
InChIKey=MHFMTUBUVQZIRE-WINRQGAFSA-N
InChI=1S/C43H53N5O8S/c1-6-28-25-43(28,41(52)46-57(53,54)31-16-17-31)45-39(50)36-22-30(26-48(36)40(51)33(42(2,3)4)23-38(49)47-19-11-8-12-20-47)56-37-24-34(27-13-9-7-10-14-27)44-35-21-29(55-5)15-18-32(35)37/h6-7,9-10,13-15,18,21,24,28,30-31,33,36H,1,8,11-12,16-17,19-20,22-23,25-26H2,2-5H3,(H,45,50)(H,46,52)/t28-,30-,33-,36+,43-/m1/s1
Sovaprevir (formerly ACH-1625) is an oral, once-daily, small molecule inhibitor of HCV protease being developed by Achillion Pharmaceuticals for the treatment of Hepatitis C. ACH-1625 is a linear peptidomimetic inhibitor that non-covalently binds to HCV NS3 protease with high potency and specificity. Short-term monotherapy of HCV genotype-1 infection with ACH-1625 was found to be safe and resulted in ≥3.3 log(10) IU/ml mean viral load reduction. Sovaprevir was developed as a therapy for patients with chronic HCV. Approximately 550 patients already have been treated with the drug in two phase 2 studies with 12-week treatment programs. One study included treatment with sovaprevir combined with pegylated interferon and ribavirin, and the other monitored the use of sovaprevir in combination with ACH-3102, Achillions second-generation NS5A inhibitor. In the second study, all of the patients with HCV genotype 1b achieved sustained virologic response.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01849562
Hepatitis C, Chronic: Sovaprevir 200-400 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C281
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Sovaprevir
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
PRIMARY | |||
|
2ND9V3MN6O
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
PRIMARY | |||
|
DTXSID00142994
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
PRIMARY | |||
|
DB12069
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
PRIMARY | |||
|
C152411
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
PRIMARY | |||
|
YY-83
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
PRIMARY | |||
|
1001667-23-7
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105750
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
PRIMARY | |||
|
9531
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
PRIMARY | |||
|
100000175095
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
PRIMARY | |||
|
53362096
Created by
admin on Sat Dec 16 17:11:06 GMT 2023 , Edited by admin on Sat Dec 16 17:11:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY